Board of Directors

We lead the synthetic biology industry, having developed and successfully commercialized the most Lab-to-Market™ ingredients. Our sustainable ingredients are used in thousands of top global brands, including our own family of consumer brands in Clean Beauty and Health markets.

As part of our mission to make renewables mainstream, our Board is lead by individuals with impressive business and industry credentials, several of which hold significant ownership stakes in Amyris directly or via their companies or affiliated entities.

John Doerr
2006

John Doerr is a Partner at Kleiner Perkins Caufield & Byers, a venture capital firm, since 1980. Mr. Doerr currently serves on the board of directors of Alphabet, Bloom Energy, and Quantumscape. Previously, Mr. Doerr served on the board of directors of Amazon.com, Inc. Mr. Doerr holds a Bachelor of Science and a Master of Science in Electrical Engineering degrees from Rice University and a Master of Business Administration degree from Harvard University.

Chair of the Nominating and Governance Committee

Geoffrey Duyk M.D., Ph.D
2012

Dr. Duyk is partner at Circularis Partners, an investment firm focused on supporting technology-enabled companies that advance the circular economy, promote sustainability, and enhance resource efficiency. Prior to Circularis, Dr. Duyk was the managing director and partner of TPG Alternative & Renewable Technologies (ART)/TPG Biotechnology from 2004 to 2017. Prior to joining TPG, Dr. Duyk served on the Board of Directors and was President of Research and Development at Exelixis. Prior to Exelixis, he was one of the founding scientific staff at Millennium Pharmaceuticals and served as Vice President of Genomics. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor at Harvard Medical School (HMS) in the Department of Genetics, and an Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk holds a Ph.D. and M.D. from Case Western Reserve University. He completed his medical and fellowship training at the University of California, San Francisco. While at UCSF, Dr. Duyk was a fellow of the Lucille P. Markey Foundation and was also awarded a post-doctoral fellowship from HHMI. He is a Fellow of the American Association for the Advancement of Science. Dr. Duyk currently serves on the Board of Directors of Anuvia Plant Nutrients; Concentric Ag; and Regen. He is a trustee of Case Western Reserve University where he Chairs the finance committee and is a member of the executive committee and investment committee. Dr. Duyk is also a member of the Institute Board of Directors of the Moffitt Cancer Center where he Chairs the R&D committee. He serves as Chairman of the Board of OncoBay Clinical, a private contract research organization and subsidiary of Moffitt Cancer Center. Dr. Duyk previously served on the Board of Directors of the American Society of Human Genetics (ASHG) where he is currently a member of the organization’s finance committee and Chairs the investment committee. He is a member of the Scientific Advisory Board (SAB) for Lawrence Berkeley National Lab (DOE) and a member of the Advisory Board for Innovatus Capital Partners. Previously, he served as a member of the SAB for Bayer CropSciences, Jackson Labs, as well as numerous NIH advisory committees.

Member of the Audit Committee

Philip Eykerman
2017

Mr. Eykerman joined DSM in 2011 as Executive Vice-President, Corporate Strategy & Acquisitions. In this role, he was responsible for corporate and business group strategy development, budgeting and planning, improvement programs, and all M&A activities. In 2015, he was also appointed as a member of the DSM Executive Committee and at present is responsible for DSM Hydrocolloids as well as DSM Food Specialties activities. Since September 2020, he is also appointed to President Human Nutrition & Health, thereby now managing/ overseeing all the group’s activities in human nutrition & health while maintaining the responsibility for the DSM Mergers & Acquisitions activities. Next to these roles within DSM, he is also a Supervisory Board member of ChemicaInvest (DSM/CVC JV), a Supervisory Board member of AnQore TopCo B.V, and a Supervisory Board member of AOC Aliancys (DSM/CVC JV). Before joining DSM, Mr. Eykerman worked for 14 years at McKinsey & Company of which the last 9 year as a Partner and leader of McKinsey’s Chemicals Practice in the Benelux and France. He holds a master degree in Chemical Engineering from the KU Leuven (Belgium) and in Refinery Engineering from the Institut Francais du Pétrole (France).

Dr. Frank Kung
2017

Dr. Kung is a founding member of Vivo, a global healthcare investment firm founded in 1996 in Palo Alto, California. Dr. Kung started his career in the biotechnology industry in 1979 when he joined Cetus Corporation. He later co-founded Cetus Immune Corporation in 1981, which was acquired by its parent company in 1983. In 1983 he co-founded Genelabs Technologies, Inc. where he served as Chairman and CEO until 1995. During his tenure in Genelabs, he brought the company public in 1991, and built it to a 175 employee international biotech company with operations in the United States, Belgium, Singapore, Switzerland and Taiwan. Dr. Kung holds a Bachelor of Science degree in chemistry from the National Tsing Hua University in Taiwan, and a Doctor of Philosophy degree in molecular biology and a Master of Business Administration degree from the University of California, Berkeley. Dr. Kung currently serves on the board of directors of a number of healthcare and biotechnology companies.

James McCann

Elected
2019

Mr. McCann is the founder and Chairman of the board of directors of 1-800-FLOWERS.COM, Inc., a floral and gourmet foods gift retailer and distribution company founded in 1976, and served as chief executive officer of 1-800-FLOWERS.COM, Inc. from 1976 until June 2016. Mr. McCann also serves on the board of directors of International Game Technology PLC and has previously served on the board of directors of Willis Towers Watson PLC and The Scotts Miracle-Gro Company.

Chair of the Leadership, Development, Inclusion and Compensation Committee
Member of the Nominating and Governance Committee

John Melo
2007

John Melo has 30 years of combined experience as an entrepreneur and thought leader in developing and growing technology companies and as a senior executive in the Oil & Gas industry. As President and Chief Executive Officer, Mr. Melo has led Amyris through successful technology development, industrial start up, product development and commercialization and a series of funding rounds, including the initial public offering. Before joining Amyris in 2007, Mr. Melo served in various senior executive positions at BP Plc (formerly British Petroleum) most recently as President of U.S. fuels operations where he successfully led a business transformation and significantly improved the financial performance. During his tenure at BP, Mr. Melo also served as Chief Information Officer of the refining and marketing segment; Senior Advisor for e-business strategy to Lord Browne, BP group chief executive; and Director of global brand development. In this last role, he helped develop the “Helios” re-branding effort. Before joining BP, Mr. Melo was with Ernst & Young. Mr. Melo currently serves on the board of directors of Renmatix Inc., serves on the board of directors of BayBio, serves on the Bio Industrial and Environmental section governing board, is a member of the Council for the Portuguese Diaspora and is a member of Young Presidents’ Organization (YPO). He was formerly an appointed member to the U.S. section of the U.S.-Brazil CEO Forum. When not working on the mission of making sustainable chemistry mainstream or championing the eradication of malaria, John enjoys skiing, reading and time with his family on the island of Pico in the Azores, his childhood home.

Steve Mills
2018

Mr. Mills has more than 40 years of experience in the fields of accounting, corporate finance, strategic planning, risk management, and mergers and acquisitions. He served as Chief Financial Officer of the Company from May 2012 to December 2013. Prior to joining the Company, Mr. Mills had a 33-year career at Archer-Daniels-Midland Company (“ADM”), one of the world’s largest agricultural processors and food ingredient providers. At ADM, he held various senior executive roles, including Chief Financial Officer, Controller, and head of Global Strategic Planning. Since 2013, Mr. Mills has served as a consultant and advisor to clients in the private equity, agribusiness, and financial services fields. Mr. Mills currently serves on the boards of Black Hills Corporation (where he serves as chair of the board), Farmers Edge, Inc., Illinois College (where he also serves as the lead director), First Illinois Corporation (along with its wholly-owned banking subsidiary, Hickory Point Bank & Trust) and Arianna S.A. Mr. Mills holds a Bachelor of Science degree in Mathematics from Illinois College

Chair of the Audit Committee
Member of the Leadership, Development, Inclusion and Compensation Committee

Ryan Panchadsaram
2021

Ryan Panchadsaram is a partner at Foris Ventures and serves as an advisor to the Chairman at Kleiner Perkins. He has been in the role since 2016 and invests in bold founders and disruptive technologies that are tackling the climate crisis, fixing our healthcare system, and improving the way we live and work. Prior to Kleiner Perkins, Mr. Panchadsaram worked at the White House and served as the deputy chief technology officer for the United States. He helped shape how an $80 billion IT budget could be used by federal agencies to deliver on their missions in a more effective, user-centric, and data-driven way. In 2015, he served as a delegate to the United Nations to launch the Solutions Summit, a grassroots effort to spotlight the work of exceptional innovators around the world tackling the Sustainable Development Goals. In 2013, he was part of the crisis response team that rescued HealthCare.gov. This was a multi-month effort that ultimately led to the Affordable Care Act providing healthcare to 31 million people. Prior to government service, he was a health technology entrepreneur and worked at Microsoft and Salesforce.com. Mr. Panchadsaram holds a Bachelor of Science degree in Industrial Engineering and Operations Research from U.C. Berkeley.

Member of the Audit Committee
Member of the Leadership, Development, Inclusion and Compensation Committee

Lisa Qi

Elected
2019

Lisa has pioneered the development of feminine Chinese brands for Daling Family. She partnered with former Estee Lauder CTO, Harvey Gedeon and award-winning Harvard Medical School skin management expert Dr. Rothaus, founding La Nature Research Center in New York. Together they created the Native Beauty skin wellness line. With Rosa Dwyer, ex-chief of formula for Estée Lauder Group, she developed Color Lock – a wellness line specially formulated for Chinese women's skin. Prior to Daling, Lisa served as Brand Director of Dupont Lycra (Hong Kong & China) and lead it to its current top-of-market position in China. She then served as the youngest Chief Representative of YSL China in France in the company’s history.

Member of the Nominating and Governance Committee

Julie Spencer Washington

Elected
2020

Julie Spencer Washington is an accomplished senior executive with a distinguished career in marketing spanning leading companies like Trinity Health, Champion Petfoods, Procter & Gamble, Gillette, Nestlé Purina, Jamba Juice, and Luxottica. In each of her leadership positions, Julie has driven sustainable corporate growth and profitability through a keen understanding of consumer needs and behaviors, market dynamics and digital trends (including social media). Julie has also leveraged her special gift for developing and motivating high-performing teams to further impact corporate success. Currently, Julie serves as Chief Marketing & Communications at Trinity Health, a Catholic health care delivery system that  serves more than 30 million people across 22 states. She is responsible for the strategic leadership of marketing, brand building, demand creation, internal and crisis communications and community engagement. Julie is committed to community improvement and, in parallel with her professional responsibilities, has a long, varied history of board service. She currently serves on the board of directors of Union Institute and University. Julie’s professional and community accomplishments have earned national attention, including selection of Black Enterprise’s “Top Women Executives in Advertising & Marketing ” (2016 and 2013), Savoy magazine’s “Top 100 Most Influential Blacks in Corporate America” (2020, 2018 and 2010), and Marketers That Matter’s “Top B2C Marketing Executive of the Year” (2013). Julie holds a Master of Business Administration degree from Washington University, a Bachelor of Arts degree in Chemistry and Psychology from Emory University, and an Executive in Education Certificate on Driving Digital and Social Strategy from Harvard University. A champion of diversity and inclusion, Julie has helped companies build more effective teams.

Member of the Leadership, Development, Inclusion and Compensation Committee